|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The prognostic role of microsatellite instability, codon‐specific KRAS , and BRAF mutations in colon cancer显示文摘 | Chun‐Chi Lin Jen‐Kou Lin Tzu‐Chen Lin Wei‐Shone Chen Shung‐Haur Yang Huann‐Sheng Wang Yuan‐Tzu Lan Jeng‐Kai Jiang Muh‐Hwa Yang Shih‐Ching Chang | 2014 | J. Surg. Oncol2014，，4： | 1 |
| 2 | Eye - hand coordination of elderly people who practice Tai Chi Chuan 显示文摘 | Yu Cheng Pei Shih - Wei Chou Pay - Shih Lin | 2008 | J For Med Associa2008，107，2： | 1 |
| 3 | Systemic and bronchoalveolar cytokines as predictors of in-hospital mortality in severe community-acquired pneumonia显示文摘 | Yao-Ling Lee Wei Chen Ling-Yun Chen Chia-Hung Chen Yu-Chao Lin Shinn-Jye Liang Chuen-Ming Shih | 2010 | Journal of Critical Care2010，，1： | 1 |
| 4 | Multiprocessor task scheduling in multistage hybrid flow-shop: an ant colony system ap- proach显示文摘 | Kuo Ching Shih Wei Lin | 2007 | International Journal of Production Research2007，4，16： | 1 |
| 5 | Mesenchymal Stem Cells Prolong Composite Tissue Allotransplant Survival in a Swine Model显示文摘 | Yur-Ren Kuo Shigeru Goto Hsiang-Shun Shih Feng-Sheng Wang Chien-Chih Lin Chun-Ting Wang Eng-Yen Huang Chao-Long Chen Fu-Chan Wei Xin Xiao Zheng W.P Andrew Lee | 2009 | Transplantation2009，，12： | 1 |
| 6 | Noninvasive Diagnosis of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Splenic Doppler Impedance Index显示文摘 | Chen–Hua Liu Shih–Jer Hsu Jou–Wei Lin Juey–Jen Hwang Chun–Jen Liu Pei–Ming Yang Ming–Yang Lai Pei–Jer Chen Jun–Herng Chen Jia–Horng Kao Ding–Shinn Chen | 2007 | Clinical Gastroenterology and Hepatology2007，，10： | 1 |
| 7 | BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy显示文摘 | Hao‐Wei Teng Yu‐Chung Huang Jen‐Kou Lin Wei‐Shone Chen Tzu‐Chen Lin Jeng‐Kai Jiang Chueh‐Chuan Yen Anna Fen‐Yau Li Hsei‐Wei Wang Shih‐Ching Chang Yuan‐Tzu Lan Chun‐Chi Lin Huann‐Sheng Wang Shung‐Haur Yang | 2012 | J Surg Oncol2012，，2： | 1 |
| 8 | The Emerging Role of SOX2 in Cell Proliferation and Survival and Its Crosstalk with Oncogenic Signaling in Lung Cancer显示文摘 | Yu‐Ting Chou Chih‐Chan Lee Shih‐Hsin Hsiao Sey‐En Lin Sheng‐Chieh Lin Chih‐Hung Chung Chi‐Hsiu Chung Yu‐Rong Kao Yuan‐Hung Wang Chien‐Tsun Chen Yau‐Huei Wei Cheng‐Wen Wu | 2013 | Stem Cells2013，，12： | 1 |
| 9 | Organisational knowledge creation strategies : A conceptual framework 显示文摘 | Yang Chen -Wei Fang Shih -Chieh Lin Julia L | 2010 | Interna- tional Journal of Information Management2010，30，3： | 1 |
| 10 | A triple combination of atorvastatin, celecoxib and tipifarnib stronglyinhibits pancreatic cancer cells and xenograft pancreatic tumors显示文摘 | Ning Ding Xiao-Xing Cui Zhi Gao Huarong Huang Xingchuan Wei Zhiyun Du Yong Lin Weichung Shih Arnold Rabson Allan Conney Chunhong Hu Xi Zheng | 2014 | International Journal of Oncology2014，，6： | 1 |
| 11 | Intra‐operative management of low portal vein flow in pediatric living donor liver transplantation显示文摘 | Ting‐Lung Lin Li‐Wei Chiang Chao‐Long Chen Shih‐Hor Wang Chih‐Che Lin Yueh‐Wei Liu Chee‐Chien Yong Tsan‐Shiun Lin Wei‐Feng Li Bruno Jawan Yu‐Fan Cheng Tai‐Yi Chen Allan M. Concejero Chih‐Chi Wang | 2012 | Transplant International2012，，5： | 1 |
| 12 | Particle swarm optimization for parameter determination and feature selection of support vector machines显示文摘 | Lin Shih Wei Ying Kuo Ching Chen Shih Chieh | 2008 | Expert Systems with Applications2008，，35： | 1 |
| 13 | A Prospective and Randomized Comparison of Limited Versus Extensive Atrial Substrate Modification After Circumferential Pulmonary Vein Isolation in Nonparoxysmal Atrial Fibrillation显示文摘 | YENN‐JIANG LIN SHIH‐LIN CHANG LI‐WEI LO YU‐FENG HU ERIC CHONG TZE‐FAN CHAO FA‐PO CHUNG JONAN LIAO CHENG‐HUNG LI HSUAN‐MING TSAO TSAIR KAO YUN‐YU CHEN JIN‐LONG HUANG SHIH‐ANN CHEN | 2014 | J Cardiovasc Electrophysiol2014，，： | 1 |
| 14 | Target‐controlled infusion of propofol versus intermittent bolus of a sedative cocktail regimen in deep sedation for gastrointestinal endoscopy: Comparison of cardiovascular and respiratory parameters显示文摘 | Wei‐Hung Chan Shih‐Lun Chang Ching‐Shuan Lin Mei‐Jyh Chen Shou‐Zen Fan | 2014 | Journal of Digestive Diseases2014，，1： | 1 |
| 15 | Postoperative retroperitoneal desmoid tumor mimics recurrent gastrointestinal stromal tumor:A case report显示文摘Desmoid tumor is a locally invasive,myofibroblastic,nonmetastatic tumor.Its pathogenesis remains unclear and it may involve genetic abnormalities,sex hormones and traumatic injury,including surgery.Postoperative intra-abdominal desmoid tumor is rare,especially in the retroperitoneum.We report a case of postoperative retroperitoneal desmoid tumor that developed 29 mo after the first excision of a gastrointestinal stromal tumor.Sporadic trauma-related intraabdominal desmoid tumors reported in the English literature are also reviewed.Despite an extremely low incidence,postoperative desmoid tumor should be considered in the differential diagnosis when a recurrent neoplasm is found at least one year after operation.However,it is a clinical challenge to distinguish recurrent malignant neoplasms from desmoid tumors,and surgical resection is the treatment option depending on the anatomic location. | Liang-Yu Shih Chang-Kuo Wei Chih-Wen Lin Chih-En Tseng | 2012 | World Journal of Gastroenterology2012，18，42： | 1 |
| 16 | Outcomes of long storage times for cryopreserved vascular grafts in outflow reconstruction in living donor liver transplantation显示文摘 | Chih‐Chi Wang Salvador Lopez‐Valdes Ting‐Lung Lin Anthony Yap Chee‐Chien Yong Wei‐Feng Li Shih‐Ho Wang Chih‐Che Lin Yueh‐Wei Liu Tsan‐Shiun Lin Allan M. Concejero Hock‐Liew Eng Douglas Henry Yu‐Fan Cheng Bruno Jawan Chao‐Long Chen | 2014 | Liver Transpl2014，，2： | 1 |
| 17 | No Additional Cholesterol-Lowering Effect Observed in the Combined Treatment of Red Yeast Rice and Lactobacillus Casei in Hyperlipidemic Patients:A Double-Blind Randomized Controlled Clinical Trial显示文摘Objective:To observe the effect of combining red yeast rice and Lactobacillus casei(L.casei)in lowering cholesterol in patients with primary hyperlipidemia,the later has also been shown to remove cholesterol in in vitro studies.Methods:A double-blind clinical trial was conducted to evaluate the cholesterol-lowering effect of the combination of red yeast rice and L.casei.Sixty patients with primary hyperlipidemia were recruited and randomized equal y to either the treatment group(red yeast rice+L.casei)or the control group(red yeast rice+placebo).One red yeast rice capsule and two L.casei capsules were taken twice a day.The treatment lasted for 8 weeks,with an extended follow-up period of 4 weeks.The primary endpoint was a difference of serum low-density lipoprotein cholesterol(LDL-C)level at week 8.Results:At week 8,the LDL-C serum level in both groups was lower than that at baseline,with a decrease of 33.85±26.66 mg/dL in the treatment group and 38.11±30.90 mg/dL in the control group;however,there was no statistical difference between the two groups(P>0.05).The total cholesterol was also lower than the baseline in both groups,yet without a statistical difference between the two groups.The only statistical y significant difference between the two groups was the average diastolic pressure at week 12,which dropped by 2.67 mm Hg in the treatment group and increased by 4.43 mm Hg in the placebo group(P<0.05).The antihypertensive activity may be associated with L.casei.Red yeast rice can significantly reduce LDL-C,total cholesterol and triglyceride.Conclusion:The combination of red yeast rice and L.casei did not have an additional effect on lipid profiles. | Chien-Ying Lee Min-Chien Yu Wu-Tsun Perng Chun-Che Lin Ming-Yung Lee Ya-Lan Chang Ya-Yun Lai Yi-Ching Lee Yu-Hsiang Kuan James Cheng-Chung Wei Hung-Che Shih | 2017 | Chinese Journal of Integrative Medicine2017，23，8： | 1 |
| 18 | Efficacy and Safety of Herbal Medicine Yun-Cai Tea in the Treatment of Hyperlipidemia:A Double-Blind Placebo-Controlled Clinical Trial显示文摘Objective:Animal studies have demonstrated a lipid-modulating effect of yun-cai tea.However,little is known about the lipid-lowering effect in humans.The aim of this study was to evaluate the lipid lowering effects and safety of yun-cai tea in patients with elevated lipid levels in a human clinical trial.Methods:This was a 12-week,randomly assigned,parallel-group,double-blind,and placebo-controlled pilot clinical study.Sixty pdmary hyperlipidemia patients were included and randomly assigned to the yun-cai tea group(30 patients)and the placebo group(30 patients),for 8 weeks of treatment and 4 weeks of follow-up.The primary endpoint was changes in plasma low-density lipoprotein-cholesterol(LDL-C)at 8 weeks.The secondary endpoints included total cholesterol(TC)and triglyceddes(TG).Results:Our results revealed no statistically significant differences in LDL-C and TC between the two groups.Despite the lack of a statistically significant difference in the level of TG between the two groups,a declining trend was noted.A significant reduction of TG was observed in the yun-cai tea group at week 8,compared to baseline(P--0.048).The incidence of stomach discomfort,gastroesophageal reflux,diarrhea,and constipation was slightly higher in the yun-cai tea group.No other significant adverse events were found.Conclusions:it is unlikely that yun-cai tea used had a blood lipid reduction effect.Further larger scale clinical tdals with a longer duration and larger dose are necessary. | Chien-Ying Lee Min-Chien Yu Chun-Che Lin Ming-Yung Lee James Cheng-Chung Wei Hung-Che Shih | 2015 | Chinese Journal of Integrative Medicine2015，21，8： | 0 |
| 19 | Outreach onsite treatment with a simplified pangenotypic directacting anti-viral regimen for hepatitis C virus micro-elimination in a prison显示文摘BACKGROUND Prisoners are at risk of hepatitis C virus(HCV)infection,especially among the people who inject drugs(PWID).We implemented an outreach strategy in combination with universal mass screening and immediate onsite treatment with a simplified pan-genotypic direct-acting antivirals(DAA)regimen,12 wk of sofosbuvir/velpatasvir,in a PWID-dominant prison in Taiwan.AIM To implement an outreach strategy in combination with universal mass screening and immediate onsite treatment with a simplified pan-genotypic DAA regimen in a PWID-dominant prison in Taiwan.METHODS HCV-viremic patients were recruited for onsite treatment program for HCV micro-elimination with a pangenotypic DAA regimen,12 wk of sofosbuvir/velpatasvir,from two cohorts in Penghu Prison,either identified by mass screen or in outpatient clinics,in September 2019.Another group of HCV-viremic patients identified sporadically in outpatient clinics before mass screening were enrolled as a control group.The primary endpoint was sustained virological response(SVR12,defined as undetectable HCV ribonucleic acid(RNA)12 wk after end-of-treatment).RESULTS A total of 212 HCV-viremic subjects were recruited for HCV micro-elimination campaign;91 patients treated with sofosbuvir/Ledipasvir or glecaprevir/pibrentasvir before mass screening were enrolled as a control.The HCV microelimination group had significantly lower proportion of diabetes,hypertension,hyperlipidemia,advanced fibrosis and chronic kidney diseases,but higher levels of HCV RNA.The SVR12 rate was comparable between the HCV microelimination and control groups,95.8%(203/212)vs 94.5%(86/91),respectively,in intent-to-treat analysis,and 100%(203/203)vs 98.9%(86/87),respectively,in perprotocol analysis.There was no virological failure,treatment discontinuation,and serious adverse event among sofosbuvir/velpatasvir-treated patients in the HCV micro-elimination group.CONCLUSION Outreach mass screening followed by immediate onsite treatment with a simplified pangenotypic DAA regimen,sofosbuvir/velpatasvir,provides successful strategies toward HCV micro-elimination among prisoners. | Chun-Ting Chen Ming-Ying Lu Meng-Hsuan Hsieh Pei-Chien Tsai Tsai-Yuan Hsieh Ming-Lun Yeh Ching-I Huang Yi-Shan Tsai Yu-Min Ko Ching-Chih Lin Kuan-Yu Chen Yu-Ju Wei Po-Yao Hsu Cheng-Ting Hsu Tyng-Yuan Jang Ta-Wei Liu Po-Cheng Liang Ming-Yen Hsieh Zu-Yau Lin Chung-Feng Huang Jee-Fu Huang Chia-Yen Dai Wan-Long Chuang Yu-Lueng Shih Ming-Lung Yu | 2022 | World Journal of Gastroenterology2022，28，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员